Age‐varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults
Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the...
Saved in:
Published in | Addiction (Abingdon, England) Vol. 114; no. 2; pp. 278 - 293 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.02.2019
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aims
We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested.
Design
Time‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age.
Setting and Participants
Adolescent data (V‐HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n = 36 309) were collected from a representative sample from the United States (2012–13).
Measurements
Mental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria.
Findings
For youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU.
Conclusions
Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety. |
---|---|
AbstractList | AimsWe tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested.DesignTime‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age.Setting and ParticipantsAdolescent data (V‐HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n = 36 309) were collected from a representative sample from the United States (2012–13).MeasurementsMental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria.FindingsFor youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU.ConclusionsSignificant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety. We tested the age-varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Time-varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. Adolescent data (V-HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10-year period (2003-13). Adult cross-sectional data (NESARC-III; n = 36 309) were collected from a representative sample from the United States (2012-13). Mental health symptoms were assessed using self-report measures of diagnostic symptoms. CU was based on frequency of past-year use. Past-year CUD was based on DSM-5 criteria. For youth in the V-HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16-19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19-20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26-27 only. For adults in the NESARC-III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early-onset CU. Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety. Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. Setting and Participants Adolescent data (V‐HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n = 36 309) were collected from a representative sample from the United States (2012–13). Measurements Mental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria. Findings For youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU. Conclusions Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety. Abstract Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. Setting and Participants Adolescent data (V‐HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n = 36 309) were collected from a representative sample from the United States (2012–13). Measurements Mental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria. Findings For youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [ b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 ( b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 ( b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 ( b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 ( b = 0.22, 95% CI = 0.10, 0.33) to age 65 ( b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 ( b = 0.96, 95% CI = 0.19, 1.73) to age 61 ( b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 ( b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU. Conclusions Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety. |
Author | Leadbeater, Bonnie J. Ames, Megan E. Linden‐Carmichael, Ashley N. |
AuthorAffiliation | 1 Department of Psychology University of Victoria Victoria BC Canada 2 Department of Biobehavioral Health, Edna Bennett Pierce Prevention Research Center, 303 Biobehavioral Health The Pennsylvania State University University Park PA, USA |
AuthorAffiliation_xml | – name: 1 Department of Psychology University of Victoria Victoria BC Canada – name: 2 Department of Biobehavioral Health, Edna Bennett Pierce Prevention Research Center, 303 Biobehavioral Health The Pennsylvania State University University Park PA, USA |
Author_xml | – sequence: 1 givenname: Bonnie J. surname: Leadbeater fullname: Leadbeater, Bonnie J. organization: University of Victoria – sequence: 2 givenname: Megan E. orcidid: 0000-0001-7871-7421 surname: Ames fullname: Ames, Megan E. email: mames@uvic.ca organization: University of Victoria – sequence: 3 givenname: Ashley N. orcidid: 0000-0001-8187-6538 surname: Linden‐Carmichael fullname: Linden‐Carmichael, Ashley N. organization: The Pennsylvania State University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30276906$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1u1DAUhS1URKeFBS-ALLFCIq3_4sQbpFHLn1SJDawtx76ZusrYwU5asmPHlmfkSfDMlAoWeGNZ97vnHt9zgo5CDIDQc0rOaDnnxrkzKkStHqEV5ZJURAh-hFZEybpiVJBjdJLzDSGkaZV4go45YY1URK7Qj_UGfn3_eWvS4sMGQ9-DnTKOPbYmBNP5jOcMuE_wdYZgF2yCw87nmBwkHAPOy3ac4nbfMubFXsfs82vsYEyQsy_ErsOEbx6mBfvydHGAbCGUMfuSm4cpP0WPezNkeHZ_n6Iv795-vvhQXX16__FifVXZ8iVV8Q4Ed30DTqimdU7UDIjg1rYCutpRaBVhtCEcWKdM7yQXjHeEk65zRkrLT9Gbg-44d1twOxvJDHpMfltWoKPx-t9K8Nd6E2-1rKlijBeBl_cCKZaV5EnfxDmF4lkzKhlvuaSkUK8OlE0x5wT9wwRK9C4zXTLT-8wK--JvSw_kn5AKcH4A7vwAy_-V9Pry8iD5GwVdpuU |
CitedBy_id | crossref_primary_10_1016_j_jad_2021_11_067 crossref_primary_10_1017_S0033291720005449 crossref_primary_10_1177_1078390320945791 crossref_primary_10_1111_add_16284 crossref_primary_10_1016_j_drugalcdep_2020_108332 crossref_primary_10_1016_j_comppsych_2024_152469 crossref_primary_10_1177_07067437211043393 crossref_primary_10_3390_ijerph191710873 crossref_primary_10_1016_j_neuropharm_2022_109155 crossref_primary_10_1093_ijnp_pyac056 crossref_primary_10_3389_fpsyt_2022_973988 crossref_primary_10_1016_j_drugpo_2021_103381 crossref_primary_10_3390_brainsci12030388 crossref_primary_10_1177_0706743719895195 crossref_primary_10_1007_s40501_020_00202_2 crossref_primary_10_1016_j_psychres_2023_115190 crossref_primary_10_1089_can_2022_0343 crossref_primary_10_2174_0929867328666210623144658 crossref_primary_10_1016_j_drugalcdep_2022_109531 crossref_primary_10_1016_j_josat_2023_209267 crossref_primary_10_1097_CXA_0000000000000124 crossref_primary_10_3389_fpsyt_2020_00859 crossref_primary_10_3390_molecules28062791 crossref_primary_10_1007_s00213_021_06001_8 crossref_primary_10_1016_j_drugalcdep_2019_107719 crossref_primary_10_1080_00221325_2022_2130025 crossref_primary_10_1007_s10578_021_01280_w crossref_primary_10_1016_j_pmedr_2023_102304 crossref_primary_10_1007_s12325_019_01151_w crossref_primary_10_1186_s13034_021_00403_4 crossref_primary_10_7759_cureus_27394 crossref_primary_10_1080_09687637_2020_1715920 crossref_primary_10_1007_s00737_022_01210_2 crossref_primary_10_1007_s11469_019_00201_2 crossref_primary_10_1080_10826084_2023_2267111 crossref_primary_10_1080_08897077_2021_1876200 crossref_primary_10_1016_j_janxdis_2023_102808 crossref_primary_10_1177_02698811221108956 crossref_primary_10_3389_fpsyt_2021_625158 crossref_primary_10_3390_ijerph18073652 crossref_primary_10_1007_s11469_022_00956_1 crossref_primary_10_1080_15504263_2023_2226588 crossref_primary_10_1186_s12889_020_09089_3 crossref_primary_10_3390_brainsci10020097 crossref_primary_10_1371_journal_pone_0263533 crossref_primary_10_1080_10826084_2024_2342008 crossref_primary_10_1177_20503245221095228 crossref_primary_10_1159_000530331 crossref_primary_10_1017_S0033291723000399 crossref_primary_10_1016_j_clinthera_2023_04_002 crossref_primary_10_1016_j_neuropharm_2021_108626 crossref_primary_10_1001_jamanetworkopen_2021_13025 crossref_primary_10_1007_s11469_024_01275_3 crossref_primary_10_1016_j_yfrne_2020_100841 crossref_primary_10_1017_S0033291724000990 crossref_primary_10_1097_01_NPR_0000733712_67456_43 crossref_primary_10_3390_epidemiologia5010007 crossref_primary_10_3390_ijms22157861 crossref_primary_10_1523_JNEUROSCI_1165_19_2019 crossref_primary_10_3389_fpubh_2024_1346207 crossref_primary_10_3390_ijms22189989 crossref_primary_10_1007_s40429_022_00461_4 |
Cites_doi | 10.1016/j.jaac.2016.12.014 10.1089/can.2016.0010 10.1186/2042-6410-3-14 10.1016/S0140-6736(11)60512-6 10.1136/jech-2016-208145 10.1111/j.1469-7610.2008.01970.x 10.1001/archpsyc.62.6.593 10.1016/S0140-6736(07)61162-3 10.1111/add.13826 10.1016/B978-0-12-804791-0.00008-2 10.1016/j.jad.2015.12.045 10.1136/bmj.325.7374.1195 10.1038/sj.npp.1301643 10.1111/j.1360-0443.2012.04015.x 10.1037/0021-843X.107.1.128 10.1017/S0954579413000643 10.1016/j.jaac.2010.05.017 10.1016/j.drugalcdep.2012.10.015 10.1176/appi.books.9780890425596 10.1016/j.drugalcdep.2007.08.005 10.1037/0033-295X.115.2.291 10.1007/s00127-002-0541-z 10.1016/j.schres.2006.07.023 10.1080/15374416.2012.694608 10.1080/00952990.2016.1213273 10.1016/S0140-6736(13)61611-6 10.1016/j.bbr.2015.04.008 10.1016/j.addbeh.2015.05.014 10.1037/cbs0000090 10.1136/bmj.325.7374.1212 10.1016/j.drugalcdep.2013.12.013 |
ContentType | Journal Article |
Copyright | 2018 The Authors. published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. 2019 Society for the Study of Addiction |
Copyright_xml | – notice: 2018 The Authors. published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. – notice: 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. – notice: 2019 Society for the Study of Addiction |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QG 7TK 8BJ FQK JBE K9. NAPCQ 5PM |
DOI | 10.1111/add.14459 |
DatabaseName | Wiley-Blackwell Titles (Open access) Wiley-Blackwell Backfiles (Open access) Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Animal Behavior Abstracts Neurosciences Abstracts International Bibliography of the Social Sciences (IBSS) International Bibliography of the Social Sciences International Bibliography of the Social Sciences ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium International Bibliography of the Social Sciences (IBSS) Neurosciences Abstracts Animal Behavior Abstracts |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Social Welfare & Social Work |
DocumentTitleAlternate | Bonnie J. Leadbeater et al |
EISSN | 1360-0443 |
EndPage | 293 |
ExternalDocumentID | 10_1111_add_14459 30276906 ADD14459 |
Genre | article Research Support, Non-U.S. Gov't Multicenter Study Journal Article |
GeographicLocations | United States British Columbia |
GeographicLocations_xml | – name: British Columbia – name: United States |
GrantInformation_xml | – fundername: National Institute on Drug Abuse funderid: P50 DA039838 – fundername: Canadian Institutes of Health Research funderid: #146615; SHI‐155410; #130500; #192583; #79917; #88476 – fundername: Michael Smith Foundation for Health Research funderid: #16637 – fundername: CIHR grantid: SHI-155410 – fundername: CIHR grantid: 192583 – fundername: Michael Smith Foundation for Health Research grantid: 16637 – fundername: NIDA NIH HHS grantid: R01 DA039854 – fundername: CIHR grantid: 79917 – fundername: CIHR grantid: 88476 – fundername: CIHR grantid: 130500 – fundername: CIHR grantid: 146615 – fundername: NIDA NIH HHS grantid: P50 DA039838 – fundername: Canadian Institutes of Health Research grantid: #146615; SHI‐155410; #130500; #192583; #79917; #88476 – fundername: Michael Smith Foundation for Health Research grantid: #16637 – fundername: National Institute on Drug Abuse grantid: P50 DA039838 |
GroupedDBID | --- ..I .3N .GA .GJ .Y3 0-V 04C 05W 0R~ 10A 1OB 1OC 23M 24P 2QV 31~ 33P 36B 3SF 3V. 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6PF 702 7PT 7RV 7X7 8-0 8-1 8-3 8-4 8-5 88E 8C1 8FI 8FJ 8G5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABOCM ABPVW ABQWH ABUWG ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACHQT ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOJX ADOZA ADXAS ADZJE ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFKRA AFPWT AFRAH AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALSLI ALUQN AMBMR AMYDB AN0 ARALO ASPBG ATUGU AVWKF AZBYB AZFZN AZQEC AZVAB BAFTC BCR BCU BDRZF BEC BENPR BFHJK BGRYB BHBCM BKEYQ BLC BMSDO BMXJE BNQBC BPHCQ BROTX BRXPI BVXVI BY8 C45 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DC6 DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO DWQXO DXH EAD EAP EAS EBB EBC EBD EBS EBX ECF ECT EIHBH EJD EMB EMK EMOBN EPS ESI ESTFP ESX EX3 F00 F01 F04 F5P FD6 FEDTE FUBAC FYUFA FZ0 G-S GNUQQ GODZA GUQSH H.X HF~ HGLYW HMCUK HVGLF HZI HZ~ H~9 IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M0O M1P M2M M2O MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NAPCQ NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PCD PQQKQ PROAC PSQYO PSYQQ Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SJFOW SUPJJ SV3 TEORI TUS UB1 UKHRP UPT V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQ9 WQJ WRC WUP WVDHM WXI WXSBR XG1 XIF XOL YFH YUY ZGI ZZTAW ~IA ~WT ADMHG CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QG 7TK 8BJ FQK JBE K9. 5PM |
ID | FETCH-LOGICAL-c4439-3be43df7ed4978dd452e043cc84eb5d1e89021703e2b9afd63423b030bbda66c3 |
IEDL.DBID | 24P |
ISSN | 0965-2140 |
IngestDate | Tue Sep 17 21:02:46 EDT 2024 Thu Oct 10 18:56:31 EDT 2024 Fri Aug 23 01:13:01 EDT 2024 Wed Oct 16 00:45:08 EDT 2024 Sat Aug 24 00:43:55 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Adolescence anxiety early onset mental health cannabis use cannabis use disorder marijuana young adulthood depression psychosis |
Language | English |
License | Attribution-NonCommercial-NoDerivs 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4439-3be43df7ed4978dd452e043cc84eb5d1e89021703e2b9afd63423b030bbda66c3 |
ORCID | 0000-0001-7871-7421 0000-0001-8187-6538 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fadd.14459 |
PMID | 30276906 |
PQID | 2162383610 |
PQPubID | 37458 |
PageCount | 16 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6519223 proquest_journals_2162383610 crossref_primary_10_1111_add_14459 pubmed_primary_30276906 wiley_primary_10_1111_add_14459_ADD14459 |
PublicationCentury | 2000 |
PublicationDate | February 2019 |
PublicationDateYYYYMMDD | 2019-02-01 |
PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Abingdon – name: Hoboken |
PublicationTitle | Addiction (Abingdon, England) |
PublicationTitleAlternate | Addiction |
PublicationYear | 2019 |
Publisher | Blackwell Publishing Ltd John Wiley and Sons Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: John Wiley and Sons Inc |
References | 2011; 377 2002; 37 2013; 25 2013; 108 2017; 43 2005; 62 1994 2013; 382 2008; 33 2017; 112 2008; 92 2014; 136 2010; 49 2016; 1 2015; 49 2012; 3 2017; 71 2007; 370 2009; 50 2006; 88 2017; 56 1998; 107 2018 2016; 298 2002; 325 2017 1983 2013; 130 2008; 115 2015 2014 2018; 50 2013 2016; 193 2012; 41 e_1_2_7_6_1 Li R. (e_1_2_7_31_1) 2017 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 Derogatis L. (e_1_2_7_28_1) 1983 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 |
References_xml | – volume: 33 start-page: 2505 year: 2008 end-page: 2516 article-title: Blunted psychotomimetic and amnestic effects of Δ‐9‐ tetrahydrocannabinol in frequent users of cannabis publication-title: Neuropsychopharmacology – year: 1983 – volume: 130 start-page: 101 year: 2013 end-page: 108 article-title: Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions publication-title: Drug Alcohol Depend [internet] – volume: 41 start-page: 719 year: 2012 end-page: 730 article-title: Co‐occurring trajectories of symptoms of anxiety, depression, and oppositional defiance from adolescence to young adulthood publication-title: J Clin Child Adolesc Psychol – volume: 92 start-page: 239 year: 2008 end-page: 247 article-title: Likelihood of developing an alcohol and cannabis use disorder during youth: association with recent use and age publication-title: Drug Alcohol Depend – volume: 50 start-page: 416 year: 2009 end-page: 423 article-title: The brief child and family phone interview (BCFPI): rationale, development, and description of a computerized children's mental health intake and outcome assessment tool publication-title: J Child Psychol Psychiatry – volume: 382 start-page: 1575 year: 2013 end-page: 1586 article-title: Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010 publication-title: Lancet – volume: 43 start-page: 442 year: 2017 end-page: 455 article-title: Cannabis and development of dual diagnoses: a literature review publication-title: Am J Drug Alcohol Abuse – volume: 88 start-page: 142 year: 2006 end-page: 150 article-title: Disturbances of visual information processing in early states of psychosis and experimental delta‐9‐tetrahydrocannabinol altered states of consciousness publication-title: Schizophr Res – volume: 1 start-page: 166 year: 2016 end-page: 175 article-title: Sex differences in cannabis use and effects: a cross‐sectional survey of cannabis users publication-title: Cannabis Cannabinoid Res – volume: 50 start-page: 17 year: 2018 end-page: 28 article-title: Marijuana trajectories in Canadian youth: associations with substance use and mental health publication-title: Can J Behav Sci – volume: 112 start-page: 1653 year: 2017 end-page: 1657 article-title: Cannabis, psychosis and schizophrenia: unravelling a complex interaction publication-title: Addiction – volume: 49 start-page: 33 year: 2015 end-page: 39 article-title: Gender differences in the associations among marijuana use, cigarette use, and symptoms of depression during adolescence and young adulthood publication-title: Addict Behav – volume: 25 start-page: 1325 year: 2013 end-page: 1345 article-title: Adolescent brain development in normality and psychopathology publication-title: Dev Psychopathol – volume: 108 start-page: 124 year: 2013 end-page: 133 article-title: The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood publication-title: Addiction – volume: 325 start-page: 1195 year: 2002 end-page: 1198 article-title: Cannabis use and mental health in young people: cohort study publication-title: BMJ – volume: 136 start-page: 85 year: 2014 end-page: 91 article-title: Investigation of sex‐dependent effects of cannabis in daily cannabis smokers publication-title: Drug Alcohol Depend – year: 2014 – year: 1994 – volume: 370 start-page: 319 year: 2007 end-page: 328 article-title: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review publication-title: Lancet – start-page: 183 year: 2018 end-page: 197 – volume: 3 start-page: 14 year: 2012 article-title: Sex differences in the neural mechanisms mediating addiction: A new synthesis and hypothesis publication-title: Biol Sex Differ – volume: 325 start-page: 1212 year: 2002 end-page: 1213 article-title: Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study publication-title: BMJ – volume: 49 start-page: 980 year: 2010 end-page: 989 article-title: Lifetime prevalence of mental disorders in U.S. adolescents: results from the national comorbidity survey replication‐adolescent supplement (NCS‐A) publication-title: J Am Acad Child Adolesc Psychiatry – volume: 37 start-page: 199 year: 2002 end-page: 206 article-title: Marijuana use and the risk of major depressive episode: epidemiological evidence from the United States National Comorbidity Survey publication-title: Soc Psychiatry Psychiatr Epidemiol – volume: 107 start-page: 128 year: 1998 end-page: 140 article-title: Development of depression from preadolescence to young adulthood: emerging gender differences in a 10‐year longitudinal study publication-title: J Abnorm Psychol – volume: 298 start-page: 15 year: 2016 end-page: 26 article-title: Sex differences in behavior and neural development and their role in adolescent vulnerability to substance use publication-title: Behav Brain Res [internet] – volume: 62 start-page: 593 year: 2005 end-page: 602 article-title: Lifetime prevalence and age‐of‐onset distributions of DSM‐IV disorders in the National Comorbidity Survey Replication publication-title: Arch Gen Psychiatry – volume: 56 start-page: 214 year: 2017 end-page: 225 article-title: Evidence for the risks and consequences of adolescent cannabis exposure publication-title: J Am Acad Child Adolesc Psychiatry – volume: 71 start-page: 811 year: 2017 end-page: 816 article-title: Association of cannabis use with the development of elevated anxiety symptoms in the general population: a meta‐analysis publication-title: J Epidemiol Community Health – year: 2017 – volume: 377 start-page: 2093 year: 2011 end-page: 2102 article-title: Global burden of disease in young people aged 10–24 years: a systematic analysis publication-title: Lancet – volume: 193 start-page: 103 year: 2016 end-page: 108 article-title: Cannabis use, depression and anxiety: a 3‐year prospective population‐based study publication-title: J Affect Disord – volume: 115 start-page: 291 year: 2008 end-page: 313 article-title: The ABCs of depression: integrating affective, biological, and cognitive models to explain the emergence of the gender difference in depression publication-title: Psychol Rev – year: 2015 – year: 2013 – ident: e_1_2_7_6_1 doi: 10.1016/j.jaac.2016.12.014 – ident: e_1_2_7_19_1 doi: 10.1089/can.2016.0010 – ident: e_1_2_7_37_1 doi: 10.1186/2042-6410-3-14 – ident: e_1_2_7_2_1 doi: 10.1016/S0140-6736(11)60512-6 – ident: e_1_2_7_8_1 doi: 10.1136/jech-2016-208145 – ident: e_1_2_7_29_1 doi: 10.1111/j.1469-7610.2008.01970.x – ident: e_1_2_7_17_1 doi: 10.1001/archpsyc.62.6.593 – ident: e_1_2_7_33_1 doi: 10.1016/S0140-6736(07)61162-3 – ident: e_1_2_7_4_1 doi: 10.1111/add.13826 – volume-title: TVEM (Time‐Varying Effect Model) SAS Macro Users’ Guide year: 2017 ident: e_1_2_7_31_1 contributor: fullname: Li R. – ident: e_1_2_7_7_1 doi: 10.1016/B978-0-12-804791-0.00008-2 – ident: e_1_2_7_11_1 doi: 10.1016/j.jad.2015.12.045 – ident: e_1_2_7_22_1 doi: 10.1136/bmj.325.7374.1195 – ident: e_1_2_7_15_1 doi: 10.1038/sj.npp.1301643 – ident: e_1_2_7_10_1 doi: 10.1111/j.1360-0443.2012.04015.x – ident: e_1_2_7_20_1 doi: 10.1037/0021-843X.107.1.128 – ident: e_1_2_7_12_1 doi: 10.1017/S0954579413000643 – ident: e_1_2_7_18_1 doi: 10.1016/j.jaac.2010.05.017 – ident: e_1_2_7_36_1 doi: 10.1016/j.drugalcdep.2012.10.015 – ident: e_1_2_7_25_1 doi: 10.1176/appi.books.9780890425596 – ident: e_1_2_7_13_1 doi: 10.1016/j.drugalcdep.2007.08.005 – ident: e_1_2_7_21_1 doi: 10.1037/0033-295X.115.2.291 – ident: e_1_2_7_14_1 doi: 10.1007/s00127-002-0541-z – ident: e_1_2_7_16_1 doi: 10.1016/j.schres.2006.07.023 – ident: e_1_2_7_24_1 doi: 10.1080/15374416.2012.694608 – ident: e_1_2_7_5_1 doi: 10.1080/00952990.2016.1213273 – ident: e_1_2_7_3_1 doi: 10.1016/S0140-6736(13)61611-6 – ident: e_1_2_7_35_1 doi: 10.1016/j.bbr.2015.04.008 – ident: e_1_2_7_23_1 doi: 10.1016/j.addbeh.2015.05.014 – ident: e_1_2_7_30_1 doi: 10.1037/cbs0000090 – ident: e_1_2_7_27_1 – ident: e_1_2_7_32_1 – ident: e_1_2_7_9_1 doi: 10.1136/bmj.325.7374.1212 – ident: e_1_2_7_34_1 doi: 10.1016/j.drugalcdep.2013.12.013 – volume-title: SCL‐90‐R: Administration, Scoring and Procedures: Manual II year: 1983 ident: e_1_2_7_28_1 contributor: fullname: Derogatis L. – ident: e_1_2_7_26_1 |
SSID | ssj0007894 |
Score | 2.5665305 |
Snippet | Aims
We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and... We tested the age-varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and... Abstract Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in... AimsWe tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 278 |
SubjectTerms | Adolescence Adolescent Adolescents Adult Adults Age Age differences Age Distribution Age of onset Anxiety Anxiety disorders Anxiety Disorders - epidemiology Anxiety Disorders - etiology British Columbia - epidemiology Cannabis cannabis use cannabis use disorder Child & adolescent psychiatry Cross-Sectional Studies depression Depressive Disorder - epidemiology Depressive Disorder - etiology Drug abuse Drug addiction Drug use early onset Females Humans Males Marijuana Marijuana Abuse - complications Marijuana Abuse - epidemiology Marijuana Smoking - epidemiology Mental depression Mental disorders Mental health Prospective Studies Psychosis Psychotic Disorders - epidemiology Psychotic Disorders - etiology Psychotic symptoms Research Report Research Reports Sex differences Symptoms Teenagers United States - epidemiology Young Adult young adulthood Young adults |
Title | Age‐varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fadd.14459 https://www.ncbi.nlm.nih.gov/pubmed/30276906 https://www.proquest.com/docview/2162383610 https://pubmed.ncbi.nlm.nih.gov/PMC6519223 |
Volume | 114 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Pa9swFH506WWXsa3d5i4booyywwy1LcsOO4VmoQxaxlhYbka_vJm2comTsdx667V_Y_-SPkm211AGvQjbkoztz-_pk_T0CeBDHmGrkHAeKh2xkMqYhrnmWUhHLFciS2ki7HjHySk7ntGv83S-BZ-7tTBeH6IfcLOW4fy1NXAumntGjoZpZybT0RPYtooxVjg_pt96N5zlbhdEq24SxtiNaGWFbBhPX3WzMXrAMB8GSt4nsK4Fmj6HZy11JGOP9QvY0uYlDP36WvJTn5d8ockB6S7Ui7MduB7_0rdXN3_wNbGNIm30BqlLgp_UcFE1ZNVoUi58RPWacKOIahU5SW1Is764XNYXropfsdVUzSfSB9AaV4Obvzb2k1R4-k8iymdZgY9mF2bTLz-OjsN274VQUuQoYSI0TVSZaWW3oFOKprE-pImUOdUiVZG285MRugsdixEvFbNKggI9hhCKMyaTVzAwtdFvgJRMSiWFkCLJKKbYQ2KpQmciJBOHsQpgvwOhuPQSG0XXNUGkCodUAMMOnqK1sqaIIyRveYIMMIDXHqn-DnY-1oowB5BtYNgXsLramzmm-u30tRmyWmRNAXx0aP__oYrxZOIO9h5f9C08Rc418oHfQxgsFyv9DnnNUrx3_y-mk-_xHZWV-KI |
link.rule.ids | 230,315,783,787,888,1378,11574,27936,27937,46064,46306,46488,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VcoALlHdgAQshxIFUTew4WamXFUu1QNsDakUvKPIrsCp1qs0uopx665XfyC9hbCdplwoJcYmSOE4c2zPz2R5_A_C8SNAqUCFibRIeM5WyuDAij9mQF1rmGaPSzXfs7PLJPnt3kB2swGa3FybwQ_QTbk4yvL52Au4mpC9IOUqmW5rMhlfgKoo7dYEbxh_OyaPywodBdPQmcYrjiJZXyPnx9FmXrdEliHnZU_IigvUmaOsmfOoKHzxPDtcXc7mufvzB6_i_f7cGN1psSkahM92CFWNvwyBs4CUfzddKzAx5Qbob9ezwDpyNPptfpz-_4ZfQCJLWPYTUFcE2s0JOG7JoDKlmwWX7hAiriW4pP0ltSXNydDyvj3yWsCWsmTavSO-ha30OYb8751IyxctzDqqQ5BhEmruwv_Vm7_UkboM7xIohCIqpNIzqKjfaxbjTmmWp2WBUqYIZmenEuAXQBPWRSeVQVJo7qkKJKklKLThX9B6s2tqaB0AqrpRWUipJc4ZHHILxTKO2korLjVRH8Kxr5PI4cHiU3dgHq7n01RzBoGv-shXjpkwTRIcFRYgZwf3QE_o3uAVfx_IcQb7UR_oHHHH3coqdfvEE3hxhM8KyCF76LvD3QpWj8difPPz3R5_Ctcnezna5_Xb3_SO4jgBvGLzMB7A6ny3MYwRRc_nEy8pvQ-Qb2A |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT9wwEB1RKqFeUCm0DSythSrEoZFI4jhZcVqxrOgX4gCCW-Sv0FWLs9osqNy4ceU38ksY20nKClXqJUriOEryMjPP9vgZ4FMeYVRIOA-VjlhIZUzDXPMspH2WK5GlNBG2v-PHETs8pV_P0_MF2Gvnwnh9iK7DzVqG89fWwCeqfGLkaJh2ZDLtv4CXFGm4Fc6P6XHnhrPcrYJo1U3CGJsRjayQTePpqs4Ho2cM83mi5FMC6yLQ6DUsN9SRDDzWK7CgzRvo-fm15Ez_LvlUk23Snqimv1bhbnChH27vr_E1MUaRJnuDVCXBT2q4GNfkqtaknPqM6hvCjSKqUeQklSH1zeVkVl26Kn7GVj2uP5Mugda4Gtz8sbmfZIyHfyWifJEV-KjX4HR0cLJ_GDZrL4SSIkcJE6FpospMK7sEnVI0jfUuTaTMqRapirQdn4zQXehY9HmpmFUSFOgxhFCcMZm8hUVTGf0eSMmkVFIIKZKM4hZbSCxV6EyEZGI3VgFstSAUEy-xUbRNE0SqcEgF0GvhKRorq4s4QvKWJ8gAA3jnkeruYMdjrQhzANkcht0FVld7vsSMfzp9bYasFllTADsO7X8_VDEYDt3O-v9f-hGWjoej4vuXo28b8ArpV9_ngPdgcTa90ptIcWbig_uVHwGVwfpN |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Age-varying+effects+of+cannabis+use+frequency+and+disorder+on+symptoms+of+psychosis%2C+depression+and+anxiety+in+adolescents+and+adults&rft.jtitle=Addiction+%28Abingdon%2C+England%29&rft.au=Leadbeater%2C+Bonnie+J&rft.au=Ames%2C+Megan+E&rft.au=Linden-Carmichael%2C+Ashley+N&rft.date=2019-02-01&rft.eissn=1360-0443&rft.volume=114&rft.issue=2&rft.spage=278&rft_id=info:doi/10.1111%2Fadd.14459&rft_id=info%3Apmid%2F30276906&rft.externalDocID=30276906 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0965-2140&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0965-2140&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0965-2140&client=summon |